Live price temporarily unavailable.
Relmada Therapeutics (RLMD) is a Health Care company in the Russell 2000. Latest news and coverage below.
| FY2016Jun 2016 | FY2017Jun 2017 | FY2018Jun 2018 | FY2019Dec 2019 | FY2020Dec 2020 | FY2021Dec 2021 | FY2022Dec 2022 | FY2023Dec 2023 | FY2024Dec 2024 | FY2025Dec 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||
| Operating income | −$16.2M | −$7.22M | −$6.92M | −$15.1M | −$60.8M | −$125.7M | −$161.2M | −$103.7M | −$83.9M | −$59.1M |
| Net income | −$2.97M | −$6.29M | −$8.96M | −$15.0M | −$59.5M | −$125.8M | −$157.0M | −$98.8M | −$80.0M | −$57.4M |
| EPS (diluted) | −$4.16 | −$8.32 | −$2.86 | −$1.62 | −$3.81 | −$7.16 | −$5.30 | −$3.28 | −$2.65 | −$1.45 |
| Balance sheet | ||||||||||
| Cash and equivalents | $8.50M | $1.71M | $2.24M | $36.3M | $2.50M | $44.4M | $5.40M | $4.09M | $3.86M | $3.50M |
| Total assets | $10.2M | $2.84M | $3.05M | $117.1M | $118.2M | $223.3M | $152.9M | $97.6M | $45.8M | $94.0M |
| Total liabilities | $3.20M | $1.38M | $8.56M | $1.46M | $12.6M | $15.1M | $12.5M | $12.2M | $10.3M | $7.49M |
| Shareholders' equity | $7.04M | $1.46M | −$5.51M | $115.7M | $105.6M | $208.3M | $140.4M | $85.4M | $35.5M | $86.5M |
| Cash flow | ||||||||||
| Operating cash flow | −$13.1M | −$6.47M | −$6.00M | −$12.1M | −$27.8M | −$91.9M | −$103.8M | −$51.7M | −$51.8M | −$45.8M |
| Capital expenditure | $562.3K | $49.7K | $12.4K | $84.8M | $182.1M | — | — | — | — | — |
| Free cash flow | −$13.7M | −$6.52M | −$6.01M | −$96.9M | −$209.9M | — | — | — | — | — |
| Q3 FY24Sep 2024 | Q4 FY24†Dec 2024 | Q1 FY25Mar 2025 | Q2 FY25Jun 2025 | Q3 FY25Sep 2025 | Q4 FY25†Dec 2025 | Q1 FY26Mar 2026 | Q2 FY26Jun 2026 | |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Operating income | −$23.0M | −$19.1M | −$18.2M | −$10.2M | −$10.3M | −$20.3M | −$19.5M | −$15.0M |
| Net income | −$21.7M | −$18.7M | −$17.6M | −$9.87M | −$10.1M | −$19.9M | −$19.1M | −$12.9M |
| EPS (diluted) | −$0.72 | −$0.62 | −$0.58 | −$0.30 | −$0.30 | −$0.27 | −$0.22 | −$0.11 |
| Balance sheet | ||||||||
| Cash and equivalents | $1.48M | $3.86M | $1.15M | $1.35M | $1.38M | $3.50M | $9.78M | $11.3M |
| Total assets | $55.7M | $45.8M | $27.7M | $21.1M | $14.9M | $94.0M | $235.4M | $219.1M |
| Total liabilities | $8.10M | $10.3M | $5.24M | $5.17M | $5.41M | $7.49M | $16.6M | $12.5M |
| Shareholders' equity | $47.6M | $35.5M | $22.4M | $15.9M | $9.47M | $86.5M | $218.7M | $206.6M |
| Cash flow | ||||||||
| Operating cash flow | −$16.7M | −$8.80M | −$18.1M | −$6.40M | −$6.72M | −$14.6M | −$15.1M | −$9.61M |
| Share buybacks | — | — | — | — | — | — | $3.36M | $6.46M |
From Relmada Therapeutics's 10-K, 10-KT and 10-Q filings with the SEC; its fiscal year ends in December. Each period shows the latest figure the company has reported for it, including restatements. † Quarter derived from the company's year-to-date or full-year totals. Filings on SEC EDGAR →
No recent news mentioning Relmada Therapeutics in our feed yet.